{"name":"Esteve Pharmaceuticals, S.A.","slug":"esteve-pharmaceuticals-s-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Tramadol (Ultram®)","genericName":"Tramadol (Ultram®)","slug":"tramadol-ultram","indication":"Moderate to moderately severe pain","status":"phase_3"}]}],"pipeline":[{"name":"Tramadol (Ultram®)","genericName":"Tramadol (Ultram®)","slug":"tramadol-ultram","phase":"phase_3","mechanism":"Tramadol is a centrally acting opioid analgesic that works by binding to opioid receptors in the brain and spinal cord, reducing pain perception.","indications":["Moderate to moderately severe pain","Severe pain"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQRkdBVnhJRFB4Nk5TWWsxeFFJZUFOVzRDdFBPTGNiOV9RMmt4ak5JdkwtUFl2US00eUFqd2hwU3Q2eXd1eW5lV2dXMGhjc1hEblRCNDg0MXdJUHF6c0N1TU1MWnVKZ2RDZ3ZPc2ZMa09ReF9ZNzJlTWlVV1ZRS0pJNS1JVUZ4Mi1QVi1iMElndWY5TmpJVVE?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Market Driver Insights: The Impact of Recent Advances on the Adrenocortical Carcinoma Market - openPR.com","headline":"Market Driver Insights: The Impact of Recent Advances on the Adrenocortical Carcinoma Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxObFR1T05NY29HMjNRb2lzVHVGT2F2d2RoWjhsd2R3dm1rbGVfYkpSVHNjTzU2T2xDNVo2TnpKUkxZQS1tVk8tN3lLdERPQ1RBZ3F2cUZtbEtFeFoxWGgzQnp1VHZZOFBqR192bG9PRmxteWhNLVBrdkk3YVBqUjFMbTVHT0k5ZzgxRS1PYkJmYXBlQUYwb05FTE1GMEctaUFyODVvQW91OXJwQQ?oc=5","date":"2026-02-10","type":"pipeline","source":"Packaging Insights","summary":"The Pharmaceutical Manufacturing and Packaging Congress 2026 - Packaging Insights","headline":"The Pharmaceutical Manufacturing and Packaging Congress 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPU0E0TF8xR1Z6ZjN0bnVBY3JCTVVKcEdKMjJmQWFVa1Q3alhHU24xWkxjMkl2YnMxMTluRFNuWDhTbFhQbzdIOXowSzRaZjFtMWtpTkhOdy1wSjgtYXBBUXBwYnAxMVl1NEYtUy1jdXk5LUFNb2NZZUMzVFd5NEZURjNkbDhxUjRFNG1ucVFrVjhNQjdDVTB0a3hLWnY?oc=5","date":"2026-01-19","type":"deal","source":"The Pharma Letter","summary":"Esteve to acquire TerSera therapeutics business unit - The Pharma Letter","headline":"Esteve to acquire TerSera therapeutics business unit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxOb3NIWlpzdUZjUWQxaHpEeUt2czBjVHRpbW56ZkNLWENSV0VfdTB4UXVRR1ZrRFlYNndFM1ZvcjJua3ZTSTJKTzVrcy1IQjNOSzl1X1NuMmlWR3UtRWJKX2hLeGhoWGFqejJkNWg1M05jYl9EZzR1UzcwNVUyZnF6MXhyeUdVdy16MDZuWHdBdEhIN0oyQkd2U1JtanBlMUFmeHBaVzhmZktmcXpnR0k4TUx0RWRCb3JPS3pqdXRLaXJRZVpxeEhXNlNrb1M3WjFkdkVHZjZIMGVuR0tWd3h2bXNsNUhGaTZqbTFvQmFHTzM?oc=5","date":"2026-01-13","type":"deal","source":"PR Newswire","summary":"ESTEVE to acquire TerSera Therapeutics' Infusion Specialty Therapies Business Unit, Expanding U.S. presence - PR Newswire","headline":"ESTEVE to acquire TerSera Therapeutics' Infusion Specialty Therapies Business Unit, Expanding U.S. presence","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxOci1DVjZZZUs1a2dqbi14clkyeFdlMXg5WHc0OG9wUzFnMHc4V09UaFpHQWhqN3h5c2FESUpmdTRkVWt1Q0JKLXR0WTRYV05OQ0NwME9ZRHZlM2JPOGxLTXo4b1M2cVNKS3dvZVRxVTNDcjZYQlhGcWRvSFE1TmxmUjV6a0IxYWZwT3lHMjFzLWtkSGRSVkhZMFJad3hDNGp0cmdnU3lGaUFpQjhmSndtUEM3dVl3VndiLVdNb2JVVjlZUVNoZ25veA?oc=5","date":"2025-07-31","type":"deal","source":"PR Newswire","summary":"ESTEVE Acquires Regis Technologies, expanding U.S. presence and capabilities - PR Newswire","headline":"ESTEVE Acquires Regis Technologies, expanding U.S. presence and capabilities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOQ2ZOZG5lTDRBMEF0dFUwQWR6c1JGVzhVWDNVWE0weU5lLWwxNE1FYnV2ak14WXZWUHZmMXhYZjFXQjc5eVRYQzJRQmp6MkN2MmgzNDRvUWpHRmFibDBRWGFXMkJLRVpmS2NTX2syQzNvSXo5Mnc1SkJPZk9tTDM4Y0FCcVV1dy1VaTh2TnNqeWdpREE3SHRENFBJWnJDc1kyLS1QSG1LZjM3dS1SVExWbXFudEhGeFE?oc=5","date":"2025-06-30","type":"deal","source":"PR Newswire","summary":"ESTEVE to acquire medicine to treat medullary thyroid cancer - PR Newswire","headline":"ESTEVE to acquire medicine to treat medullary thyroid cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOajVZMVp4NktlR05ITm9fX3Nua3dQR2p5WF9zSzRDMGJhdElJczBONFVDb2xxLS0zczRLYzZOSWN1TnJFdXh2Qnd3cHF0U1NVc1AzeC1qZ01Rc0Ftb01yOXF3c1pid1BqMElMLTNQM3B1RnZqRDJXRFdUZUh0TEozVDBXZmZqMF9hSV93?oc=5","date":"2025-04-01","type":"pipeline","source":"The Pharma Letter","summary":"Esteve signs a licensing agreement with Eton Pharma - The Pharma Letter","headline":"Esteve signs a licensing agreement with Eton Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPMXdfVUR1SGc1Tk1CenN6OTV1bkhRRjgtTzI0UExIckNCWkhFaEZJQzFLZlhLUGI2cFo5eGdZTUllY2VucDg2UjM4eG1GX0tPQ3c1RW55dndOcTYwS25KSjNyUV9HREZ0RFpfNU5CTEtIWVJLYUtRZnMtdTd3U1U3aHluR2xnd2JhWVVN?oc=5","date":"2025-02-12","type":"pipeline","source":"Iberian Lawyer","summary":"White & Case with Takeda in asset sale to Hikma and Esteve - Iberian Lawyer","headline":"White & Case with Takeda in asset sale to Hikma and Esteve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPd2diZWpXTk5XM21iblNaQjl1OTFNYURXNk1TTEFSVjBlakE1c1V1Q0hVQWZtRTk5WExXSy10a2xXY1FsQnBzVEdEYnJlVlJIVmVFS21qb0N1MTNGQUQxVktGMFlxdkpkTmpZOXZMOU1VWU5ZenhxUG13cWpoM0Njdy11M3RuM0p5SXluUUZ5V3hXemVjRFdtUXBMMlVLZVNuSHN6WDVFaVI?oc=5","date":"2025-02-06","type":"pipeline","source":"White & Case LLP","summary":"White & Case advises Takeda on divestment of assets to Hikma and Esteve - White & Case LLP","headline":"White & Case advises Takeda on divestment of assets to Hikma and Esteve - White & Case LLP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPaFFMVHgzMFdiNU5Gc2I2M0JXbmVhMVlWWlpXNUJKbkZQcktLYkNCOFVHR3JXdWZGVDVZVTc4SVA5a2xjazNHdDZfa1prbVpKOUN4WXRpd2NSZEZfeG1hVEVSN1ZYS0pDZ0dFeFZMRWV6clRCTzlBUjhnd2JRYzVUXzMxQ1JHY0Q3RndKYmlHdTlmUlVNcmllc2tEczE?oc=5","date":"2024-07-20","type":"pipeline","source":"Contract Pharma","summary":"West Introduces LyoSeal Cap and NovaGuard SA Pro - Contract Pharma","headline":"West Introduces LyoSeal Cap and NovaGuard SA Pro","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOdVFMbTVibmdMSE9na1AwR0FpWFBIYVYwdEYxNUR6SG9MSWx5aTViSm0xN1liRmZUaTJCWTkwYmhBV25ITUdXcVM1WTZnc0QwOFNzY3p6RmpibmJnMjVpaWk0bU1JaG5sNjRLaVdhSXZ5ck0wYUdJQ2dYQTktc3VldHhOY09HUE8tUDNZ?oc=5","date":"2023-08-24","type":"pipeline","source":"Yahoo Finance","summary":"Tofacitinib Global Market Report 2023 - Yahoo Finance","headline":"Tofacitinib Global Market Report 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOZ25NTTJUU0FtZWpmcjJZdVZKdlVhb3V3Zk1veldfYjNqc1IyS2tObG9ycndEMEVWcW9mV3VyVGh6OGxselA1bmFOdmh1RzdWN0tCN1hNTEpSeEwxWWc0UXpReVdOREswRC1aWHV3c29rRlMyeVY5bUZxby1JSGRKcjJNQUMtOUxxSlFMV2sxcHdpM1NWX1Nzd2xsaHBfZFAyUGRaU2FZYVBiRHJiZ0ZJQ01SV0kyWms?oc=5","date":"2023-01-16","type":"regulatory","source":"Pharmaceutical Technology","summary":"CMO Moves: Regulatory catalysts for therapy manufacturing -January - Pharmaceutical Technology","headline":"CMO Moves: Regulatory catalysts for therapy manufacturing -January","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}